Cargando…
The feasibility of using mutation detection in ctDNA to assess tumor dynamics
For many decades it has been known that tumor DNA is shed into the blood. As a consequence of technological limitations, researchers were unable to comprehensively characterize circulating DNA. The advent of ultrasensitive and highly specific molecular assays has provided a comprehensive profile of...
Autores principales: | Yi, Xin, Ma, Jianhui, Guan, Yanfang, Chen, Rongrong, Yang, Ling, Xia, Xuefeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434851/ https://www.ncbi.nlm.nih.gov/pubmed/28124376 http://dx.doi.org/10.1002/ijc.30620 |
Ejemplares similares
-
Clinical factors associated with circulating tumor DNA (ctDNA) in primary breast cancer
por: Zhou, Yidong, et al.
Publicado: (2019) -
ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy
por: Ma, Fei, et al.
Publicado: (2016) -
Dynamic ctDNA Mutational Complexity in Patients with Melanoma Receiving Immunotherapy
por: Fitzgerald, Sandra, et al.
Publicado: (2023) -
Response prediction by mutation- or methylation-specific detection of ctDNA dynamics in pretreated metastatic colorectal cancer
por: Doleschal, Bernhard, et al.
Publicado: (2023) -
Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond
por: Keller, Laura, et al.
Publicado: (2020)